PepGen reports mixed results from phase 2 DM1 drug trial

March 30, 2026 4:05 PM

PepGen Inc. (NASDAQ: PEPG) reported results from the 5 mg/kg dose cohort of its Phase 2 FREEDOM2 trial testing PGN-EDODM1 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found